Ready To Use Human/Mouse IgG Kits As Tools in Drug Discovery

Posted by Sandy Koshkin on Wed, Aug 24, 2011 @ 11:23 AM

Monoclonal AntibodiesThe economic recession has not inhibited the growth of FDA approved antibody drugs and the market for these drugs.  So far treatments for Cancer, Arthritis, Autoimmune diseases and Transplant rejection have dominated the class of drugs derived from monoclonal antibodies. The future products will include additional drugs for treatment of the above diseases and others such as Osteoporosis and Asthma.

Monoclonal antibody derived therapeutics have become a significant part of the overall drug market boasting over $40 billion in sales as of 2010 and is likely to double in the next ten years. The development of monoclonal  antibodies continues to grow and  clearly, faster ready-to-use kits to help rapid determination of the IgG levels in such antibodies remain important tools in the drug discovery and development process.

All major pharmaceutical and biotech companies have active programs in developing monoclonal antibodies. Smaller biotech companies focus on developing such antibodies only, whereas universities and research institutions utilize grants to discover new targets with monoclonal antibody technologies.

ADMEcell  and RD-Biotech (Besancon, France) offer a new line of Ready-To-Use 30 minute assay kits to quantitate Human, Mouse, Rat and Bovine IgG in cell culture supernatant, ascites and serum-all assays covering a wide dynamic range (i.e. 16-1000ng/ml for human IgG). Color coded buffer solutions simplify the pipetting steps.  Recombinant or fully humanized monoclonal antibodies can be assayed. Also included in the product line is the Mouse IGg sotyping kit.

Tags: Human IgG Kits, Mouse IgG Kits, Rat Igg Kits, Mouse Isotyping Kits, Monoclonal Antibodies

DMPK Labs and Integrating New In-Vitro Assays

Posted by Sandy Koshkin on Thu, Aug 04, 2011 @ 04:45 PM

DMPK Labs and Integrating New In Vitro Assays

Improve DMPK Productivity by Using the Industry Leading Solution

Determining the Drug Metabolism and PharmacoKinetic properties of a drug is crucial to understanding its safety and efficacy before the regulatory approval process takes place.

Currently, DMPK Labs have a tremendous balancing act on their hands betweenMDR1 Plated Cells getting all the routine work completed with minimal staff and deciding on handling selected new compounds. Many of these compounds can be tested in house or contracted out to CRO.  Preparing reagents and developing in-house assays require time and resources, whereas waiting for data from an outside source uses very little resources other than money. However, Ready-to-Use Assay Kits offer a simple solution to balance the resources needed and the associated costs.

So, how does a lab begin to evaluate a newer technology such as a new in vitro assay that can be very helpful long term? In the short term, it seems like there is no time available…However, the benefits  for DMPK labs are enormous  if they can dedicate some time to evaluate for example, a Ready-To-Use cell based assay such as Caco-2 or MDCR1 or Plasma Protein Binding to compare the cost and time savings with their current methods. These assays are available at a reasonable price and produce speedy and reliable results to make the life  easier in the DMPK Labs.

Tags: transporters, ELISA Kits, Human IgG Kits, Mouse IgG Kits, Ready To Use Assays, Ready To Use Kits, caco-2 assay, cell based assays, MDR1 Kits, Protein Binding Kits, Blood Brain Absorption Kits, Caco-2 Assays